Introduction
It is well known that hyperpigmentation occurs in Addison's disease (1) , in some patients who have undergone adrenalectomy for Cushing's disease (2) , and in some patients with the ectopic ACTH syndrome (3) (4) (5) (6) . Previous studies in our laboratory have shown that the principal melanocyte-stimulating factor in the plasma of such patients is different from ACTH (7, 8) but have failed to identify it more specifically. In a recent study (9) , we identified a-melanocytestimulating hormone (a-MSH) in human pituitaries and tumors by means of radioimmunoassay, but this substance accounted for only a small per-centage of the total melanocyte-stimulating activity of these tissues as determined by bioassay.
We therefore postulated that the major melanocyte-stimulating factor in human tissues and plasma might be f8-MSH. This point had already been established for pituitary tissue (10) but remained unexplored with respect to plasma or nonpituitary tumors that produce "ectopic" ACTH and MSH. In order to examine this question, it was necessary to develop a sensitive and specific radioimmunoassay for 8-MSH. The results of the radioimmunoassays were compared with those of bioassays in order to determine what proportion of the total melanocyte-stimulating activity of a given specimen could be attributed to its content of /8-MSH.
Methods
,B-MSH antisera were obtained by immunizing guinea pigs with the #-MSH contained in commercial ACTH.1 Four different treatment schedules, each lasting for about 2 months, were employed. Some guinea pigs were injected intramuscularly with unaltered commercial ACTH in doses in 40 U once a week. Some were similarly injected in doses of 20 U twice a week. Another group of guinea pigs received weekly subcutaneous inj ections containing 20 U of the commercial ACTH emulsified with Freund's complete adjuvant. The fourth group received subcutaneous injections of commercial ACTH in Freund's complete adjuvant in doses of 40 U every 2 wk. 10 days after the last injection, blood was drawn by cardiac puncture and plasma was preserved as previously described (9) . Several guinea pigs in each group were found to have developed antibodies to p-MSH. After a respite of 2 months, immunization of these guinea pigs was resumed. Five weekly intramuscular injections of 40 U of commercial ACTH alone were given to those animals previously immunized with commercial ACTH only. Five weekly subcutaneous injections of 20 U of commercial ACTH emulsified with complete Freund's adjuvant were given to those guinea pigs previously injected with this material. 10 days after the last of these injections, blood was again drawn and plasma assayed for antibodies to f3-MSH.
In preparation for radioimmunoassay, synthetic human ,f-MSH (,8h-MSH) was labeled 2 with 131I by the method of Hunter and Greenwood (11) and was then purified on a cellulose column (12) and used within 1 day to avoid accumulation of "damaged" 13h-MSH-`31I during storage and preserve the high specific activity of the labeled hormone. The labeled r-MSH employed in radioimmunoassays had specific activities of 0.5-1.0 c/mg of j8-MSH.
The binding of p-MSH-Y3'I to antibodies and its displacement by unlabeled p-MSH were studied by the chromatoelectrophoretic system of Yalow and Berson (13) . The standard diluent for the incubation mixture consisted of 100 ml of 0.075 M phosphate buffer (pH 7.2) containing 0.45 g of NaCl, 0.25 g of human serum albumin, 1 ml of normal guinea pig serum and 0.01 g of Merthiolate. Acidified human albumin solution (9) The first scan shows that, when incubated with normal guinea pig serum, flh-MSH-'3'I was "free" (F) and remained at the origin. The second scan shows that, when incubated with the antiserum, most of the Ph-MSH--3`I was "bound"
(B) and migrated with the globulin fraction. The third and fourth scans show that the addition of progressively greater quantities of unlabeled ,Bh-MSH (0.05 ng, 0.2 ng) to the mixture resulted in progressively greater displacement of radioactivity from the "bound" peak to the "free" peak and a decrease in B/F ratio. of antiserum diluted appropriately with standard diluent, and fh-MSH-R'I diluted with standard diluent so that 0.05 ml contained approximately 4000 dpm. Final antibody concentration was 1: 10,000. All tubes were prepared in duplicate. Each biological extract was assayed at three or more dilutions. The amount of "damaged" fih-MSH-'3`I produced during incubation and chromatoelectrophoresis, although usually negligible, was routinely assessed by a method previously described (9) . Incubation was carried out at 4VC for 4 days. Just before chromatoelectrophoresis 0.1 ml of normal human plasma 3 containing a trace of bromphenol blue was added to each incubation mixture to serve as a carrier. The contents of each tube were applied to a strip of Whatman 3MC paper, and the strips were subjected to chromatoelectrophoresis. The strips were dried and scanned as previously described (9) . In this system unbound (or "free") Pu-MSH-j31I remained at the origin, whereas f8h-MSH-'J'I bound to antibodies migrated with the globulin fraction. The areas under the "bound" peak (B) and "free" peak (F) were measured, and the ratio B/F was calculated. The B/F ratio was used as an index of the quantity of unlabeled #-MSH in a given tube (Fig. 1 ). Using known quantities of synthetic 6h-MSH we constructed a standard curve as a part of each experiment, and as a 3The normal subjects were pretreated overnight with 4 mg of dexamethasone, and only plasma that afforded excellent separation of the bound 8h-MSH-'119 from the free #h-MSH-12'I was used as a carrier. criterion for identifying and quantifying 6- (14) . The resultant supernatant was immediately washed twice with ethyl ether for 3 min according to the method of Yalow and coworkers (15) .
The volume of ethyl ether was 6 and 4 times that of original plasma, respectively. The aqueous phase was further purified in Amberlite CG-50 by the method of Island and coworkers (7) .
Biologic assays of melanocyte-stimulating activity were performed by the in vitro frog skin-darkening method of Shizume and coworkers (16 (17) .
Highly purified human ACTH and synthetic porcine ACTH did displace labeled Ph-MSH from the antibodies, but these polypeptides were only one-three thousandth as effective as 83h-MSH itself. The plasma and tissue extracts used in the present study were bioassayed for ACTH activity to exclude the possibility that ACTH could be present in quantities great enough to introduce an error in the pl-MSH radioimmunoassay.
Highly purified porcine /3-MSH was as active as synthetic 83h-MSH in displacing labeled Ph-MSH from the antibodies, but there is no evidence that porcine p9-MSH occurs in man. Therefore, since the starting material in all of our studies was human tissue or plasma and since significant interference could not be ascribed to a-MSH, ACTH, or any of their available analogues, it seemed reasonable to assume that the material detected by the radioimmunoassay was either human 8-MSH or a very closely related analogue. Extracts of tissues other than pituitary glands or tumors of patients with the ectopic ACTH syndrome did not contain detectable quantities of 8-MSH by radioimmunoassay.
Recovery of /3-MSH. Plasma from two normal subjects was divided into several 10-ml portions. Three portions of each were extracted and subjected to radioimmunoassay for 8-MSH. The assay results from the first subject were 0.042, 0.042, and 0.055 ng/ml (mean 0.046), and those for the second were 0.078, 0.084, and 0.090 ng/ml (mean 0.084). To other portions of the same plasma, known quantities of /3h-MSH were added before extraction and assay. The results of these assays are shown in Table I . In nine assays the recovery of f8-MSH ranged from 59 to 81% of the amount present in plasma before extraction.
Assays of human pituitary extracts. Two individual human pituitary glands were extracted and subjected to bioassay and radioimmunoassay. Radioimmunoassay results are plotted in Fig. 4 Assays of human tumor extracts (Fig. 4 , Table II). Tumor tissues of 11 patients with the ectopic ACTH syndrome were extracted and subjected to bioassay and radioimmunoassay. The parallelism between the displacement curves representing tumor extracts and that of standard j8h-MSH indicated that each tumor contained a sub- 4 Synthetic 8h-MSH has a biologic potency of approximately 3.3 X 109 U/g, expressed in the units employed by Shizume, Lerner, and Fitzpatrick (16 Assays of /-MSH in plasma of normal subjects (Fig. 4) . Extracts of plasma from seven normal subjects also displaced labeled ,1h-MSH from antibodies with displacement curves parallel to those obtained with standard unlabeled syntheticl/-MSH, but the extent of the radioimmunoassay was limited to three points for each extract, since the incubation system could accommodate only 0.02 ml of extract representing 0.6 ml of plasma. Use of larger quantities of plasma extract resulted in poor resolution of bound and free peaks. Starting with large quantities of normal plasma, we assayed two extracts both in the isolated frog skin system and by radioimmunoassay; the results of bioassays agreed closely with those obtained by radioimmunoassay. The apparent concentrations of ,8-MSH in plasma of nomal human subjects were less than 0.09 ng/ml.
Correlation between degree of hyperpigmentation and concentration of f-MSH in plasma (Fig. 5 ). An attempt was made to evaluate the clinical significance of plasma f8-MSH in patients with "addisonian" hyperpigmentataion. 1614 be useful in measuring human B-MSH by radioimmunoassay. Since the f3-MSH preparation used in the production of antisera also contained other pituitary hormones, it was important to have pure P-MSH as a test antigen. Fortunately, the antiserum clearly distinguished 8-MSH from a-MSH and ACTH, and this was important because these two polypeptides do occur in man and possess biologic MSH activity (9) .
Sensitive and specific radioimmunoassays have been needed to complement information obtained with the relatively nonspecific bioassay method. As in any immunologic assay, the specificity of the present method depends upon the validity of the assumption that "specific" 83-MSH antibodies do not cross-react to a significant degree with other compounds that might occur in the mixture to be assayed. For practical purposes, this appears to be true. Polypeptide-rich mixtures that are known to be devoid of MSH activity have failed to cause any displacement of labeled ,8-MSH from the antibodies used in the present radioimmunoassay system. Furthermore, the known structural analogues of 8-MSH that would seem most likely to occur in human tissues (a-MSH and ACTH fragments) also failed to cross-react with /8-MSH antibodies to such an extent that they would be mistaken for ,8-MSH. A compound that behaves like 8-MSH in this system is in all probability either 8-MSH or a very closely related analogue.
The MSH activity of plasma has previously been shown to be abnormally high in patients with Addison's disease (7, 8, 16) , in patients who have developed hyperpigmentation after bilateral adrenalectomy as treatment for Cushing's disease (7) (8) (9) , and in patients with hyperpigmentataion associated with the ectopic ACTH syndrome (7) (8) (9) .
In each of these conditions, plasma ACTH is characteristically elevated. The quantity of ACTH, however, is far too small to account for the amount of melanocyte-stimulating activity found by bioassay (7) (8) (9) . Furthermore, the major melanotropin of the plasma of such patients has been shown to be physically separable from the major plasma adrenocorticotropin (7, 8) . Therefore, although ACTH does have intrinsic melanocyte-stimulating activity, it does not appear to be the major pigmentary hormone of human plasma.
A similar situation has been described with regard to a-MSH (9) . This hormone was identified and quantified by radioimmunoassay in human pituitary tissue and in tumors of patients with the ectopic ACTH syndrome, but the quantities of a-MSH were too small to account for more than a minor fraction of the total biologic MSH activity in these tissues. a-MSH has yet to be identified in the plasma of either normal or hyperpigmented subjects.
The present study has shown that a third melanotropin, f8-MSH, is demonstrable in the plasma of each of the three disorders characterized by addisonian hyperpigmentation. In most cases, the quantities of total MSH as estimated by radioimmunoassay were in fairly close agreement with the quantities of total MSH as estimated by biologic assay. It seems probable, therefore, that the major pigmentary hormone in the plasma of patients with addisonian hyperpigmentataion is ,8-MSH.
Some of the tumor and plasma extracts did not show close agreement between the results of the bioassay and the results of the radioimmunoassays for 83-MSH. A number of explanations are possible. First, neither assay method is perfectly precise. The coefficient of variation for the bioassay has been found to be 23%, and that for the radioimmunoassay has been found to be 13 % in our laboratory. Some of the discrepancies, then, could be due merely to the variances of the methods. Second, some of the specimens (especially the tumors) might have undergone degenerative changes that could have affected either their biologic potency or their immunologic reactivity to some degree. Or, third, some of the specimens might originally have contained either a significant quantity of a melanocyte-stimulating factor other than ,8-MSH or a significant quantity of a biologically inactive cross-reactant with j8-MSH antibodies. Nevertheless, in most extracts most of the biologic melanocyte-stimulating activity could be accounted for by the quantity of 8-MSH found by radioimmunoassay.
The close biologic relationships among ACTH, a-MSH, and /8-MSH can be appreciated from consideration of the fact that all of these hormones have been found to accompany each other not only in pituitary tissue but also in tumors associated with the ectopic ACTH syndrome, even though the tumors themselves arose from a variety of tissues of origin. One might speculate that the synthesis and secretion of these three polypeptides might be controlled by a common mechanism.
